B-type natriuretic peptide level reduction and its predictors following sodium-glucose cotransporter 2 inhibitor treatment in patients with diabetic kidney disease: a Japan Chronic Kidney Disease Database Extension analysis
Main finding · BNP reduction >10%Result — go to the resultOdds ratio 1.497 CI 1.206–1.859Authors' conclusion
Compared with other antidiabetic drugs, SGLT2i was substantially associated with BNP reduction in a broad spectrum of DKD.
Study context
- Population
- Patients with diabetic kidney disease (DKD) in a Japanese nationwide database (71 ± 12 years, 68% men, BNP 71 [27–190] pg/mL, estimated glomerular filtration rate (eGFR) 51 ± 22 mL/min/1.73 m²)
- Participants
- 1,818 patients
- Exposure
- SGLT2i vs other antidiabetic drugs
- SGLT2in = 939
- Other antidiabetic drugsn = 879reference
- Outcome
- BNP reduction, defined as a reduction of >10%
- Follow-up
- 30-365 days after initiation
Methodological detailsnationwide database
- Nationwide database
Main finding
BNP reduction >10%
Odds ratio
1.497
CI 1.206–1.859
P < 0.001
Events by group
SGLT2ivs Other antidiabetic drugs
OR 1.497 (CI 1.206–1.859); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
Consistency of association across subgroups and endpoints
- Association consistent across eGFR, proteinuria, and multiple BNP endpoints
Predictor of BNP reduction after SGLT2i: concomitant loop diuretics
- Concomitant loop diuretics associated with a lower rate of BNP reduction after SGLT2i
Original publication
B-type natriuretic peptide level reduction and its predictors following sodium-glucose cotransporter 2 inhibitor treatment in patients with diabetic kidney disease: a Japan Chronic Kidney Disease Database Extension analysis. Diabetes Res Clin Pract. Published 15 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →